Simon Wilkinson CEO, Innate Therapeutics Clinical Trials Phase 2 in NZ for Multiple Sclerosis–OTCQX Workshop 2011
On August 23, 2011 · In Biotech, Clinical Trials, International News, Pharmaceutical, Research and Development
http://www.innatetherapeutics.com/
Learn about compassionate use in New Zealand. Innate Therapeutics Limited is a public unlisted biotech company based in Auckland, NZ.
Interesting to hear about drug development outside the US.
Tagged with: banking • Biotech • Drugs • investing • Multiple Sclerosis • New Zealand • OTCQX • pharmaceuticals
Micro-Cap Review Latest Issue
News from

NIBA Announces That FOGFUELS Will Be Attending the NIBA New York Conference June 17-19, 2013 at the Marriott Hotel Downtown New York, NY
New Malaria Crisis Presents Opportunity for Plandai
High Median Survival Rate Is Nuvilex's Trump Card
INSCOR Inc.'s New CEO Is a Major Win
NIBA Announces That Ironridge Global Partners Will Be Attending NIBA New York Conference June 17 - 19, 2013 at the Marriott Hotel Downtown New York, NY
AmericaVest CRE Mortgage Funding Trust Announcing Its Presentation at the National Investment Banking Association Conference
Goldman Small Cap Research Issues Research Report on PetroTech Oil and Gas, Inc.
Pinetree Capital Ltd. Announces Unaudited May 31, 2013 Net Asset Value Per Share of $0.95
Pinetree Capital Announces Election of Directors
Plandai Biotechnology Positions Itself in War Against Cholesterol
http://www.marketwire.comSNNLiveTV Commercial
Cavaet Emptor or Buyer Beware by SNN Inc. CEO Sheldon “Shelly” Kraft
Check out the book "Caveat Emptor" written by CEO Sheldon Kraft, click on the image to view a preview and the full book can be purchased for $15.95.
There are some best practices and good hints on what to look out for in today’s volatile markets.





